As we have shown by CD8+ T cells from tumor-draining lymph nodes as well as from the peripheral blood of patients with advanced stages of HNSCC, engaging SLAMF7 is also able to enhance T-cell responses in a presumably immunocompromised environment, where T-cell function is downregulated. This evidence concerns the gene CD8A and head and neck squamous cell carcinoma.